• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

DreaMed Diabetes wins CE Mark for insulin therapy management platform

February 15, 2018 By Sarah Faulkner

DreaMed DiabetesDreaMed Diabetes has won CE Mark clearance for its Advisor Pro decision-support platform, designed to help healthcare professionals manage insulin therapy for their Type I diabetes patients.

The company’s cloud-based platform provides personalized insulin treatment plans by combining data from insulin pumps and continuous glucose monitors. Using machine learning techniques, the system analyzes all of the data it collects from connected devices to come up with an optimized insulin dosing treatment plan.

DreaMed, in partnership with Glooko, is conducting at 112-patient study of its Advisor Pro platform. The company plans to assess the technology’s ability to adjust blood glucose levels and prevent hypoglycemic events during a six-month period as compared to recommendations by diabetes experts. DreaMed said it’s slated to announce results from the trial by the end of this year.

“DreaMed Diabetes’ mission is to simplify treatment and improve patient experience with our intelligent, personalized diabetes decision support solutions for patients and healthcare providers,” CEO Eran Atlas said in prepared remarks.

“Our product is the only diabetes decision support solution that has received regulatory approval for optimizing insulin pump therapy using continuous glucose monitoring data. We therefore believe that it will be an important companion for doctors and patients alike in achieving optimal glycemic control and the data from our clinical feasibility studies support this conclusion. We are on track with our multi-center clinical trial for Advisor Pro, and are planning a soft launch for this revolutionary product in Europe in the summer of 2018.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: DreaMed Diabetes, glooko

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS